Literature DB >> 23860084

Revised Cardiac Risk Index (RCRI) is a useful tool for evaluation of perioperative cardiac morbidity in kidney transplant recipients.

Nir Hoftman1, Adrian Prunean, Anahat Dhillon, Gabriel M Danovitch, Michael S Lee, Hans Albin Gritsch.   

Abstract

BACKGROUND: We evaluated a published Revised Cardiac Risk Index (RCRI) to determine if this preoperative cardiovascular risk stratification tool would be useful in the kidney transplant recipient population.
METHODS: We identified all kidney transplants from 2005 to 2009 (n=1652) at our institution. We performed a detailed retrospective chart review of (a) all recipients who underwent preoperative coronary angiography (n=169) and (b) an age-matched and transplantation year-matched group who did not undergo coronary angiography (n=156). Charts were reviewed for the presence of specific preoperative cardiovascular risk factors and perioperative cardiovascular complications (as defined by RCRI plus elevation of troponin) from time of surgery to hospital discharge. The total number of risk factors for each patient was compared with the occurrence of postoperative cardiac complications to identify a possible association.
RESULTS: The number of risk factors was highly predictive of cardiovascular complications (receiver operating characteristic area, 0.77; P<0.0001). History of coronary artery disease was most strongly associated (odds ratio, 20.59; confidence interval, 4.73-89.53; P=0.0001) and history of congestive heart failure was also significantly associated with cardiac complications (odds ratio, 2.95; confidence interval, 1.01-8.59; P=0.0475).
CONCLUSION: The RCRI is a useful tool for cardiac risk stratification in kidney transplantation and could be used to develop protocols for intraoperative and postoperative care to minimize complications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23860084     DOI: 10.1097/TP.0b013e31829e2703

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

Review 1.  The comparative and added prognostic value of biomarkers to the Revised Cardiac Risk Index for preoperative prediction of major adverse cardiac events and all-cause mortality in patients who undergo noncardiac surgery.

Authors:  Lisette M Vernooij; Wilton A van Klei; Karel Gm Moons; Toshihiko Takada; Judith van Waes; Johanna Aag Damen
Journal:  Cochrane Database Syst Rev       Date:  2021-12-21

2.  Prevalence and predictors of early cardiovascular events after kidney transplantation: evaluation of pre-transplant cardiovascular work-up.

Authors:  Marianne Delville; Laurent Sabbah; Delphine Girard; Caroline Elie; Sandra Manceau; Marie Piketty; Frank Martinez; Arnaud Méjean; Christophe Legendre; Rebecca Sberro-Soussan
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

3.  Clinical utility of the revised cardiac risk index in older Chinese patients with known coronary artery disease.

Authors:  Lu Che; Li Xu; Yuguang Huang; Chunhua Yu
Journal:  Clin Interv Aging       Date:  2017-12-22       Impact factor: 4.458

4.  Clinical Utility of Survivin (BIRC5), Novel Cardiac Biomarker, as a Prognostic Tool Compared to High-sensitivity C-reactive Protein, Heart-type Fatty Acid Binding Protein and Revised Lee Score in Elderly Patients Scheduled for Major Non-cardiac Surgery: A Prospective Pilot Study.

Authors:  Danica Marković; Tatjana Jevtović-Stoimenov; Vladan Ćosić; Biljana Stošić; Vesna Dinić; Bojana Marković-Živković; Radmilo J Janković
Journal:  J Med Biochem       Date:  2018-04-01       Impact factor: 3.402

5.  Comparing the Predictive Power of Preoperative Risk Assessment Tools to Best Predict Major Adverse Cardiac Events in Kidney Transplant Patients.

Authors:  Colin P Dunn; Emmanuel U Emeasoba; Ari J Holtzman; Michael Hung; Joshua Kaminetsky; Omar Alani; Stuart M Greenstein
Journal:  Surg Res Pract       Date:  2019-03-20

6.  The PER (Preoperative Esophagectomy Risk) Score: A Simple Risk Score to Predict Short-Term and Long-Term Outcome in Patients with Surgically Treated Esophageal Cancer.

Authors:  Matthias Reeh; Johannes Metze; Faik G Uzunoglu; Michael Nentwich; Tarik Ghadban; Ullrich Wellner; Maximilian Bockhorn; Stefan Kluge; Jakob R Izbicki; Yogesh K Vashist
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.